Key Points
- Protalix CEO Dror Bashan purchased 56,000 shares at an average price of $1.81 on Dec. 19 for about $101,360, bringing his stake to 188,516 shares — a 42.26% ownership increase valued at roughly $341,214.
- Stock and analyst context: PLX trades near $1.75 with a 50-day SMA of $1.98, a 12-month range of $1.32–$3.10 and a market cap of ~$140.7M; HC Wainwright cut its target from $15 to $12 but maintained a Buy rating, leaving the consensus average target at $12.
Protalix BioTherapeutics, Inc. (NYSE:PLX - Get Free Report) CEO Dror Bashan purchased 56,000 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average cost of $1.81 per share, for a total transaction of $101,360.00. Following the acquisition, the chief executive officer owned 188,516 shares of the company's stock, valued at approximately $341,213.96. The trade was a 42.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Protalix BioTherapeutics Price Performance
Protalix BioTherapeutics stock opened at $1.75 on Wednesday. The business has a 50 day simple moving average of $1.98 and a 200-day simple moving average of $1.79. Protalix BioTherapeutics, Inc. has a 12 month low of $1.32 and a 12 month high of $3.10. The stock has a market capitalization of $140.74 million, a PE ratio of -13.46 and a beta of -0.25.
Institutional Investors Weigh In On Protalix BioTherapeutics
Hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC purchased a new stake in Protalix BioTherapeutics in the first quarter valued at approximately $39,000. BNP Paribas Financial Markets raised its stake in Protalix BioTherapeutics by 126.5% during the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company's stock worth $34,000 after purchasing an additional 8,498 shares during the period. Virtu Financial LLC purchased a new position in Protalix BioTherapeutics during the third quarter worth approximately $37,000. Cascade Financial Partners LLC acquired a new position in shares of Protalix BioTherapeutics in the 2nd quarter valued at $25,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter valued at $27,000. 16.53% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, HC Wainwright decreased their target price on Protalix BioTherapeutics from $15.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 21st. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $12.00.
Get Our Latest Analysis on PLX
Protalix BioTherapeutics Company Profile
(
Get Free Report)
Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix's core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.
The company's first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
